Beijing SL Pharmaceutical Co., Ltd.

XSEC:002038 Stock Report

Market Cap: CN¥8.4b

Beijing SL Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Beijing SL Pharmaceutical's earnings have been declining at an average annual rate of -13.3%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been declining at an average rate of 15.8% per year. Beijing SL Pharmaceutical's return on equity is 1.4%, and it has net margins of 10.5%.

Key information

-13.3%

Earnings growth rate

-13.0%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate-15.8%
Return on equity1.4%
Net Margin10.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Beijing SL Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:002038 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2478282308175
30 Jun 24827129332173
31 Mar 24967285369170
31 Dec 231,018417431177
30 Sep 231,000314479166
30 Jun 231,079386530159
31 Mar 231,072373577159
01 Jan 231,050234579162
30 Sep 221,128228598172
30 Jun 221,144290609155
31 Mar 221,237397623188
01 Jan 221,215426612196
30 Sep 211,184497544231
30 Jun 211,200469553236
31 Mar 211,171395615206
31 Dec 201,113365594189
30 Sep 201,296287770125
30 Jun 201,517327850141
31 Mar 201,759348919134
31 Dec 192,0304871,000128
30 Sep 192,1925431,049103
30 Jun 192,2375781,04385
31 Mar 192,19359099569
01 Jan 192,16757197273
30 Sep 182,01967585285
30 Jun 181,757651692107
31 Mar 181,456589508100
31 Dec 171,24253441274
30 Sep 171,08548627841
30 Jun 171,0044312350
31 Mar 179784302050
31 Dec 161,0104521870
30 Sep 161,0324431900
30 Jun 161,0905001810
31 Mar 161,1385451670
31 Dec 151,1575751670
30 Sep 151,1696531380
30 Jun 151,1956671390
31 Mar 151,2327051370
31 Dec 141,2436951330
30 Sep 141,2296681520
30 Jun 141,2046431480
31 Mar 141,2196171610
31 Dec 131,1625771570

Quality Earnings: 002038 has high quality earnings.

Growing Profit Margin: 002038's current net profit margins (10.5%) are lower than last year (31.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002038's earnings have declined by 13.3% per year over the past 5 years.

Accelerating Growth: 002038's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002038 had negative earnings growth (-73.8%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).


Return on Equity

High ROE: 002038's Return on Equity (1.4%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:10
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beijing SL Pharmaceutical Co., Ltd. is covered by 16 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
YANG QIAOChangjiang Securities Co. LTD.
Shuchang LiuChangjiang Securities Co. LTD.
Jing QiangChina International Capital Corporation Limited